Adaptimmune Therapeutics
ADAP
ADAP was delisted on the 27th of October, 2025.
71 hedge funds and large institutions have $348M invested in Adaptimmune Therapeutics in 2017 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 21 increasing their positions, 17 reducing their positions, and 11 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
46% more call options, than puts
Call options by funds: $158K | Put options by funds: $108K
36% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 11
24% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 17
6% more funds holding
Funds holding: 67 → 71 (+4)
2.7% less ownership
Funds ownership: 11.96% → 9.26% (-2.7%)
16% less capital invested
Capital invested by funds: $416M → $348M (-$68.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$6.07M |
| 2 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$4.18M |
| 3 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
+$2.56M |
| 4 |
GAMA
Graticule Asia Macro Advisors
New York
|
+$1.95M |
| 5 |
Millennium Management
New York
|
+$1.66M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$3.35M |
| 2 |
Axa
Paris,
France
|
-$3.08M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.6M |
| 4 |
Renaissance Technologies
New York
|
-$1.24M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$897K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
IHM
76
Iguana Healthcare Management
New York
| – | -$205K | -25,000 | Closed |
|
|
EMG
77
Ellington Management Group
Old Greenwich,
Connecticut
| – | -$180K | -22,000 | Closed |
|
|
TI
78
Telemetry Investments
New York
| – | -$170K | -20,710 | Closed |
|
|
BIM
79
Bogle Investment Management
Newton Lower Falls,
Massachusetts
| – | -$133K | -16,320 | Closed |
|
|
NSEDCP
80
NJ State Employees Deferred Compensation Plan
Trenton,
New Jersey
| – | -$131K | -16,000 | Closed |
|
81
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$502 | +65 | New |
|
ADAP Hedge Fund Activity: Q4 2017 in Review
71 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Adaptimmune Therapeutics (ADAP) for Q4 2017, worth a combined $348M — down 16% from $416M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new ADAP positions and 11 closed out — a net gain of 4 holders — while 21 added to existing stakes and 17 trimmed.
The largest buyer was BlackRock, adding an estimated $6.07M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $3.35M sold.
- 71 institutional investors held Adaptimmune Therapeutics (ADAP) as of Q4 2017, up from 67 in Q3 2017.
- Funds reported $348M of Adaptimmune Therapeutics stock for Q4 2017, down 16% quarter-over-quarter.
- 15 funds opened new Adaptimmune Therapeutics positions in Q4 2017 and 11 closed out, a net change of +4 holders.
- The largest Adaptimmune Therapeutics buyer in Q4 2017 was BlackRock, an estimated $6.07M added.
- The largest Adaptimmune Therapeutics seller in Q4 2017 was Adage Capital Partners, an estimated $3.35M sold.
Based on aggregated 13F filings for Q4 2017.